Elion Therapeutics

Executive Summary

Elion Therapeutics is a preclinical-stage biotechnology company dedicated to combating antimicrobial resistance (AMR) through the discovery and development of novel small molecule therapeutics. Founded in 2021 and headquartered in New York, the company has raised $81 million to advance its pipeline of antibiotics targeting resistant pathogens. Leveraging modern medicinal chemistry and microbiology, Elion aims to address the growing global threat of multidrug-resistant infections. While the company remains in early preclinical stages with no publicly disclosed pipeline, its significant funding and focus on AMR—a high-priority area—position it as a promising player in infectious disease therapeutics. The company's ability to progress its lead programs into IND-enabling studies and secure additional financing will be critical to its near-term trajectory. Elion's success hinges on generating robust preclinical data to support clinical translation and navigating the challenging antibiotic development landscape.

Upcoming Catalysts (preview)

• Q4 2026Nomination of Lead Development Candidate70% success
• H1 2027IND-Enabling Studies Initiation60% success
• Q2 2027Series C Financing or Partnership Announcement50% success